In conclusion, serum IL-17A levels measured at the time of AKI diagnosis or ICU admission are differentially elevated in critically ill patients with AKI compared to those without AKI and higher levels of serum IL-17A are independently associated with higher risk of hospital mortality and MAKE, and higher ICU resource utilization. Here, IL17A is linked to acute kidney injury.